Alzheimers Disease Biomarkers Market Projected to Surpass a Valuation of USD 1.7 Billion by 2031

A recent research report by Transparency Market Research (TMR) examines the analysis of Alzheimer's disease biomarkers, forecasting a projected expansion of the global market at a Compound Annual Growth Rate (CAGR) of 7.3% during the forecast period spanning from 2022 to 2031.

Get Exclusive PDF Sample Copy of Alzheimer's Disease Biomarkers Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=44970&utm_source=OpenPR_Ajay&utm_medium=OpenPR

The prevalence of Alzheimer's disease, often affecting older individuals, is on the rise due to factors such as an aging population and lifestyle-related risks. As a result, there is a growing demand for Alzheimer's disease biomarker testing, which is anticipated to drive market growth in the coming years.

According to data from the Harvard Chan School (2020) and Alzheimer's Society (2022), the global population suffering from dementia is expected to triple over the next 30 years. The risk of developing dementia increases with age, with individuals over the age of 90 being particularly susceptible. Lifestyle factors such as alcohol consumption, physical activity, diet, sleep patterns, social engagement, and mental stimulation also play significant roles in the development of Alzheimer's disease and cognitive decline.

Key findings from the research highlight the importance of cerebrospinal fluid (CSF) biomarkers in predicting disease progression and aiding in clinical decision-making. The immunoassay technique is gaining popularity due to its cost-effectiveness and simplicity, contributing to its anticipated prominent share in the Alzheimer's disease biomarkers market.

Factors driving market growth include the increasing older population, rising prevalence of neurological diseases, and sedentary lifestyles. Regionally, North America is expected to experience notable growth, fueled by the high prevalence of neurological diseases, robust research and development activities, and the presence of key market players. Similarly, Asia Pacific is expected to witness growth due to the rising prevalence of dementia, Parkinson's disease, and Alzheimer's disease.

Key players profiled in the report include Thermo Fisher Scientific, Inc., Enzo Life Sciences, Inc., Merck KGaA, AnaSpec, Inc., Fujirebio, Cell Signaling Technology, Inc., NanoSomiX, Imagilys, 23andMe, Inc., QIAGEN, C₂N Diagnostics, Quanterix, and Quest Diagnostics.

The market segmentation includes various types of biomarkers such as CSF biomarkers, genetic biomarkers, and blood biomarkers, along with different detection techniques and end-users. The regions covered in the report include North America, Europe, Asia Pacific, and the Rest of the World.

Ask for References - https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=44970&utm_source=OpenPR_Ajay&utm_medium=OpenPR

About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.